Nanobiotix S.A.

Paris Stock Exchange NANO.PA

Nanobiotix S.A. Capital Expenditure for the year ending December 31, 2023: USD -362.03 K

Nanobiotix S.A. Capital Expenditure is USD -362.03 K for the year ending December 31, 2023, a -263.83% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Nanobiotix S.A. Capital Expenditure for the year ending December 31, 2022 was USD -99.50 K, a 62.48% change year over year.
Nanobiotix S.A. Capital Expenditure for the year ending December 31, 2021 was USD -265.24 K, a -102.92% change year over year.
Nanobiotix S.A. Capital Expenditure for the year ending December 31, 2020 was USD -130.71 K, a 91.93% change year over year.
Nanobiotix S.A. Capital Expenditure for the year ending December 31, 2019 was USD -1.62 M, a -240.37% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

Paris Stock Exchange: NANO.PA

Nanobiotix S.A.

CEO	Mr. Laurent Levy Ph.D.
IPO Date	Oct. 29, 2012
Location	France
Headquarters	60 rue de Wattignies
Employees	110
Sector	Healthcare
Industries Biotechnology 3D Printing Chemicals & Advanced Materials Clinical Trials Medical Instruments Pharmaceuticals Vaccines

Description

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

Key trends

Past 5 years